Phio Pharmaceuticals Corp.(PHIO)Earnings, Financials & Key Ratios

PHIO•NASDAQ

$1.01

Price updated Jul 7, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryRNA and Genome Editing Developers

AboutPhio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.Show more

Revenue$0
EBITDA-$9M-24.8%
Net Income-$9M-21.7%
EPS (Diluted)-1.45-59.3%
ROE-69.95%+39.1%

PHIO Price & Volume

Phio Pharmaceuticals Corp. (PHIO) stock price & volume — 10-year historical chart

Loading chart...

Persistent Clinical Burn Outpaces Capital Reserves

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Contracting

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Clinical Trial Funding Exhaustion

Key Thesis Takeaways

Phio Pharmaceuticals remains a pre-commercial biotechnology entity characterized by a total absence of revenue and an escalating R&D burn rate that reached $2.8 million in 2026Q1.
The company's reliance on external capital to fund its clinical-stage programs presents significant long-term sustainability risks, as evidenced by a $159.1 million accumulated deficit in retained earnings.
Investors should monitor the firm's ability to secure strategic partnerships or additional funding, as the current cash position of $17.0 million may be insufficient to support long-term development milestones.

Verdict Logic

the company's lack of commercial revenue and the rapid decline in cash from $21.0 million in 2025Q4 to $17.0 million in 2026Q1 suggest a high risk of further dilutive financing.

PHIO Growth Metrics

Phio Pharmaceuticals Corp. (PHIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-61.6%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM100%

Return on Capital

10 Years-104.07%

5 Years-90.37%

3 Years-102.18%

Last Year-71.54%

Latest PHIO News

Recent stock market news and headlines for Phio Pharmaceuticals Corp. (PHIO)

Newsfile Corp·Jun 26, 2026

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Live Presentation and Q&A: Tuesday, June 30, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile Corp. - June 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas.

Newsfile Corp·Jun 25, 2026

Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical

Newsfile Corp·Jun 24, 2026

Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762

Nitto Denko Avecia begins first commercial-scale cGMP production of PH-762 drug substance Newly manufactured supply will support upcoming clinical trial in next development phase King of Prussia, Pennsylvania--(Newsfile Corp. - June 24, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced that the manufacture of the first commercial-scale cGMP batch of PH-762 drug substance has commenced at Nitto Denko Avecia, Inc. Phio entered into a comprehensive drug substance services agreement with Nitto Denko Avecia, Inc. in June 2025. Under the agreement to date, Avecia has successfully concluded a series of important preliminary activities that involve analytical and process development, method validation, cGMP manufacturing, and testing services for Phio's lead clinical development compound, PH-762.

Newsfile Corp·Jun 18, 2026

Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical

Peers Comparison

Key metrics vs top competitors for Phio Pharmaceuticals Corp. (PHIO)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
PHIOPhio Pharmaceuticals Corp.Current	$1.01	$11.73M	-0.70	—	—	-69.95%	—
SRPTSarepta Therapeutics, Inc.	$19.79	$2.09B	-2.78	15.58%	2.98%	4.89%	—
ARWRArrowhead Pharmaceuticals, Inc.	$86.97	$12.25B	-7128.69	23258.15%	-48.38%	-55.09%	—
ALNYAlnylam Pharmaceuticals, Inc.	$321.59	$42.91B	138.02	65.19%	13.46%	98.29%	—
NTLAIntellia Therapeutics, Inc.	$17.43	$1.96B	-4.57	16.92%	-597.04%	-57.27%	—
BEAMBeam Therapeutics Inc.	$37.92	$3.9B	-46.81	120.01%	-49.17%	-5.89%	—